Fresenius Medical Care AG (NYSE:FMS) Stake Lowered by Valley National Advisers Inc.

Valley National Advisers Inc. cut its stake in Fresenius Medical Care AG (NYSE:FMS) by 31.6% during the fourth quarter, HoldingsChannel reports. The fund owned 7,936 shares of the company’s stock after selling 3,662 shares during the quarter. Valley National Advisers Inc.’s holdings in Fresenius Medical Care were worth $179,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Allworth Financial LP increased its position in Fresenius Medical Care by 53.1% in the 3rd quarter. Allworth Financial LP now owns 1,675 shares of the company’s stock worth $36,000 after purchasing an additional 581 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new stake in shares of Fresenius Medical Care in the 3rd quarter valued at approximately $38,000. GAMMA Investing LLC grew its stake in shares of Fresenius Medical Care by 50.4% in the 3rd quarter. GAMMA Investing LLC now owns 4,998 shares of the company’s stock valued at $106,000 after buying an additional 1,675 shares in the last quarter. ORG Wealth Partners LLC bought a new stake in Fresenius Medical Care in the third quarter worth approximately $112,000. Finally, Venturi Wealth Management LLC increased its stake in shares of Fresenius Medical Care by 1,045.8% during the 3rd quarter. Venturi Wealth Management LLC now owns 5,259 shares of the company’s stock worth $112,000 after purchasing an additional 4,800 shares during the last quarter. 8.37% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have commented on FMS. Truist Financial increased their price target on Fresenius Medical Care from $23.00 to $25.00 and gave the company a “hold” rating in a report on Monday, January 6th. Bank of America upgraded Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research note on Monday, December 2nd. Berenberg Bank initiated coverage on Fresenius Medical Care in a research report on Wednesday, November 6th. They issued a “buy” rating and a $25.60 price objective for the company. Finally, StockNews.com initiated coverage on Fresenius Medical Care in a research report on Friday, January 3rd. They set a “strong-buy” rating on the stock.

Fresenius Medical Care Stock Performance

NYSE FMS opened at $24.89 on Monday. Fresenius Medical Care AG has a twelve month low of $17.93 and a twelve month high of $25.25. The company has a quick ratio of 1.02, a current ratio of 1.37 and a debt-to-equity ratio of 0.42. The stock has a market cap of $14.60 billion, a P/E ratio of 20.57, a PEG ratio of 0.82 and a beta of 0.92. The company’s 50-day simple moving average is $23.20 and its 200 day simple moving average is $21.23.

Fresenius Medical Care (NYSE:FMS) last released its quarterly earnings data on Tuesday, November 5th. The company reported $0.45 earnings per share for the quarter, beating the consensus estimate of $0.42 by $0.03. The company had revenue of $5.23 billion for the quarter, compared to analyst estimates of $5.36 billion. Fresenius Medical Care had a return on equity of 6.04% and a net margin of 3.43%. During the same period in the prior year, the company posted $0.31 EPS. As a group, research analysts forecast that Fresenius Medical Care AG will post 1.53 earnings per share for the current fiscal year.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.